Importance: Published evidence on the long-term safety of etanercept (ETA) and adalimumab (ADA) in patients with polyarticular juvenile idiopathic arthritis (pJIA) is still limited.
Objectives: To investigate the rates of serious adverse events (SAE) and of events of special interest (ESI) under ETA and ADA treatment.
Design, Setting And Participants: Patients with pJIA were prospectively observed in the national JIA biological register, Biologika in der Kinderrheumatologie, and its follow-up register, Juvenile arthritis Methotrexate/Biologics long-term Observation.
Main Outcomes And Measures: We calculated the relative risks of SAE and ESI for ETA and ADA compared with methotrexate (MTX).
Results: Among the 1414 patients treated with ETA (n=1414; 4461 exposure years (EY)) and ADA (n=320; 493 EY), significantly more SAE, infections and medically important infections were observed (ETA: 4.5, 5.7, 0.9; ADA: 4.7, 11.4, 0.4 per 100 EY) compared with those treated with MTX alone (n=1455; 2.907 EY; 2.6, 5.5, 0.5 per 100 EY). The risk for malignancies was not significantly increased for ETA and ADA compared with MTX (0.09, 0.27 and 0.07/100 person-years). Patients under ETA monotherapy developed more frequently incident inflammatory bowel disease (IBD) and incident uveitis (0.5 and 0.8/100 EY) than patients treated by ETA in combination with MTX (0.1 and 0.2/100 EY) or MTX alone (0.03 and 0.1/100 EY).
Conclusions And Relevance: Our data confirm the acceptable long-term tolerability of ETA and ADA in pJIA. However, whether the onset of IBD and uveitis during ETA monotherapy is a paradoxical effect or an inadequate response to therapy remains unclear and requires further investigation in this growing cohort.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/annrheumdis-annrheumdis-2014-206747 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- - The study evaluated the effectiveness, safety, and immune response of Etanercept (ETA) and Adalimumab (ADA) biosimilars in children with juvenile idiopathic arthritis compared to their original drug versions.
- - After 24 months, children treated with biosimilars showed significantly lower disease activity scores and fewer harmful antibodies compared to those on the original drugs, indicating better treatment outcomes.
- - The safety of biosimilars was similar to the originators, but further research with a larger sample size is necessary to confirm these findings.
An Acceptor-Donor-Acceptor Structured Nano-Aggregate for NIR-Triggered Interventional Photoimmunotherapy of Cervical Cancer.
Adv Mater
September 2024
State Key Laboratory and Institute of Elemento-Organic Chemistry, The Centre of Nanoscale Science and Technology and Key Laboratory of Functional Polymer Materials, Renewable Energy Conversion and Storage Center (RECAST), Tianjin Key Laboratory of Functional Polymer Materials, College of Chemistry, Nankai University, Tianjin, 300071, China.
Compared with conventional therapies, photoimmunotherapy offers precise targeted cancer treatment with minimal damage to healthy tissues and reduced side effects, but its efficacy may be limited by shallow light penetration and the potential for tumor resistance. Here, an acceptor-donor-acceptor (A-D-A)-structured nanoaggregate is developed with dual phototherapy, including photodynamic therapy (PDT) and photothermal therapy (PTT), triggered by single near-infrared (NIR) light. Benefiting from strong intramolecular charge transfer (ICT), the A-D-A-structured nanoaggregates exhibit broad absorption extending to the NIR region and effectively suppressed fluorescence, which enables deep penetration and efficient photothermal conversion (η = 67.
View Article and Find Full Text PDFAdherence, persistence and treatment switching in psoriasis.
Immunotherapy
July 2024
ASL Pescara, Hospital Pharmacy.
Article Synopsis
- This study looks at how often and consistently patients with psoriasis use different drugs over 1 to 5 years, specifically focusing on medications like Adalimumab and others.
- Researchers used real-life data to measure how well patients adhered to their treatment plans using the Proportion of Days Covered (PDC) method.
- While adherence to treatment was generally good, the study found that persistence (the duration patients stay on treatment) dropped significantly after the second year, highlighting the need for better strategies to encourage long-term treatment.
TNF blockers alone and associated with Benznidazole impact in vitro cytokine dynamics in chronic Chagas disease.
Parasite Immunol
February 2024
Instituto Aggeu Magalhães-IAM/Fiocruz, Recife, Pernambuco, Brazil.
Article Synopsis
- Studies on the immune response in Chagas disease show that symptomatic patients, especially those with severe Chagas heart disease, have an inflammatory immune profile dominated by tumour necrosis factor (TNF).
- The research evaluates cytokine levels in patients with different clinical forms of Chagas disease after treatment with TNF blockers (Adalimumab and Etanercept) and benznidazole, measuring the effects on both regulatory and inflammatory cytokines.
- Results indicate that Adalimumab was more effective in blocking TNF, while Etanercept showed a specific decrease in TNF levels only in the most severe cases, suggesting that targeting TNF could be a beneficial strategy for the immunological treatment of severe Chagas heart disease.
Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry.
Ophthalmol Ther
March 2024
Department of Medicine, Surgery and Neurosciences, Ophthalmology Unit, ERN RITA Center, Policlinico "Le Scotte", University of Siena, Viale Bracci 16, 53100, Siena, Italy.
Article Synopsis
- Many biological drug patents have expired, leading to the development of biosimilar agents (BIOs), but their use in children raises concerns, prompting a study on their efficacy and safety for treating pediatric non-infectious uveitis (NIU).
- Data collected from pediatric patients treated with TNF inhibitors BIOs showed a significant decrease in flare-ups and ocular complications, as well as a reduction in the need for glucocorticoids during treatment.
- The study included 47 patients, demonstrating strong treatment retention rates and maintaining visual acuity throughout the therapy, while only recording a few minor adverse events.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!